First-in-Human Study of Orally Administered GS-441524 for COVID-19
Status:
Completed
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a two-part study is to evaluate the multi-day safety, tolerability, and
pharmacokinetics (PK) of orally administered GS-441524 in a healthy human volunteer.